🚀 VC round data is live in beta, check it out!
Oscotec Valuation Multiples
Discover revenue and EBITDA valuation multiples for Oscotec and similar public comparables like Sinopep, WAVE Life Sciences, Precigen, Corvus Pharma and more.
Oscotec Overview
About Oscotec
Oscotec Inc is engaged in drug discovery for osteoporosis, arthritis, periodontal, dental health and cancer diseases.
Founded
1998
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$1B
Oscotec Financials
Oscotec reported last 12-month revenue of $64M and EBITDA of $32M.
In the same LTM period, Oscotec generated $62M in gross profit, $32M in EBITDA, and $24M in net income.
Revenue (LTM)
Oscotec P&L
In the most recent fiscal year, Oscotec reported revenue of $68M and EBITDA of $38M.
Oscotec expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $64M | XXX | $68M | XXX | XXX | XXX |
| Gross Profit | $62M | XXX | $66M | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | 98% | XXX | XXX | XXX |
| EBITDA | $32M | XXX | $38M | XXX | XXX | XXX |
| EBITDA Margin | 51% | XXX | 57% | XXX | XXX | XXX |
| EBIT Margin | 49% | XXX | 52% | XXX | XXX | XXX |
| Net Profit | $24M | XXX | $35M | XXX | XXX | XXX |
| Net Margin | 38% | XXX | 52% | XXX | XXX | XXX |
| Net Debt | — | — | $198K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Oscotec Stock Performance
Oscotec has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Oscotec's stock price is $37.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -3.6% | XXX | XXX | XXX | $0.93 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOscotec Valuation Multiples
Oscotec trades at 21.2x EV/Revenue multiple, and 41.9x EV/EBITDA.
EV / Revenue (LTM)
Oscotec Financial Valuation Multiples
As of April 19, 2026, Oscotec has market cap of $1B and EV of $1B.
Equity research analysts estimate Oscotec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oscotec has a P/E ratio of 58.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 21.2x | XXX | 20.0x | XXX | XXX | XXX |
| EV/EBITDA | 41.9x | XXX | 35.3x | XXX | XXX | XXX |
| EV/EBIT | 43.4x | XXX | 38.4x | XXX | XXX | XXX |
| EV/Gross Profit | 21.8x | XXX | 20.4x | XXX | XXX | XXX |
| P/E | 58.9x | XXX | 40.0x | XXX | XXX | XXX |
| EV/FCF | 43.3x | XXX | 36.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Oscotec Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Oscotec Margins & Growth Rates
Oscotec's revenue in the last 12 month grew by 23%.
Oscotec's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oscotec's rule of X is 1% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Oscotec Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | (16%) | XXX | XXX | XXX |
| EBITDA Margin | 51% | XXX | 57% | XXX | XXX | XXX |
| EBITDA Growth | 37% | XXX | (38%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 1% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 28% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Oscotec Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Oscotec | XXX | XXX | XXX | XXX | XXX | XXX |
| Sinopep | XXX | XXX | XXX | XXX | XXX | XXX |
| WAVE Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Precigen | XXX | XXX | XXX | XXX | XXX | XXX |
| Corvus Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| SOTHEMA | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oscotec M&A Activity
Oscotec acquired XXX companies to date.
Last acquisition by Oscotec was on XXXXXXXX, XXXXX. Oscotec acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Oscotec
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOscotec Investment Activity
Oscotec invested in XXX companies to date.
Oscotec made its latest investment on XXXXXXXX, XXXXX. Oscotec invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Oscotec
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Oscotec
| When was Oscotec founded? | Oscotec was founded in 1998. |
| Where is Oscotec headquartered? | Oscotec is headquartered in South Korea. |
| Who is the CEO of Oscotec? | Oscotec's CEO is Scott Lee. |
| Is Oscotec publicly listed? | Yes, Oscotec is a public company listed on Korea Exchange. |
| What is the stock symbol of Oscotec? | Oscotec trades under 039200 ticker. |
| When did Oscotec go public? | Oscotec went public in 2007. |
| Who are competitors of Oscotec? | Oscotec main competitors are Sinopep, WAVE Life Sciences, Precigen, Corvus Pharma. |
| What is the current market cap of Oscotec? | Oscotec's current market cap is $1B. |
| What is the current revenue of Oscotec? | Oscotec's last 12 months revenue is $64M. |
| What is the current revenue growth of Oscotec? | Oscotec revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of Oscotec? | Current revenue multiple of Oscotec is 21.2x. |
| Is Oscotec profitable? | Yes, Oscotec is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Oscotec? | Oscotec's last 12 months EBITDA is $32M. |
| What is Oscotec's EBITDA margin? | Oscotec's last 12 months EBITDA margin is 51%. |
| What is the current EV/EBITDA multiple of Oscotec? | Current EBITDA multiple of Oscotec is 41.9x. |
| What is the current FCF of Oscotec? | Oscotec's last 12 months FCF is $31M. |
| What is Oscotec's FCF margin? | Oscotec's last 12 months FCF margin is 49%. |
| What is the current EV/FCF multiple of Oscotec? | Current FCF multiple of Oscotec is 43.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.